About: Harnessing self-assembled peptide nanoparticles in epitope vaccine design

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Harnessing self-assembled peptide nanoparticles in epitope vaccine design Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Harnessing self-assembled peptide nanoparticles in epitope vaccine design
Creator	Ghasemi, Younes Golkar, Nasim Hajighahramani, Nasim Kianpour, Sedigheh Negahdaripour, Manica Nezafat, Navid
Source	Elsevier; Medline; PMC
abstract	Abstract Vaccination has been one of the most successful breakthroughs in medical history. In recent years, epitope-based subunit vaccines have been introduced as a safer alternative to traditional vaccines. However, they suffer from limited immunogenicity. Nanotechnology has shown value in solving this issue. Different kinds of nanovaccines have been employed, among which virus-like nanoparticles (VLPs) and self-assembled peptide nanoparticles (SAPNs) seem very promising. Recently, SAPNs have attracted special interest due to their unique properties, including molecular specificity, biodegradability, and biocompatibility. They also resemble pathogens in terms of their size. Their multivalency allows an orderly repetitive display of antigens on their surface, which induces a stronger immune response than single immunogens. In vaccine design, SAPN self-adjuvanticity is regarded an outstanding advantage, since the use of toxic adjuvants is no longer required. SAPNs are usually composed of helical or β-sheet secondary structures and are tailored from natural peptides or de novo structures. Flexibility in subunit selection opens the door to a wide variety of molecules with different characteristics. SAPN engineering is an emerging area, and more novel structures are expected to be generated in the future, particularly with the rapid progress in related computational tools. The aim of this review is to provide a state-of-the-art overview of self-assembled peptide nanoparticles and their use in vaccine design in recent studies. Additionally, principles for their design and the application of computational approaches to vaccine design are summarized.
has issue date	2017-09-30(xsd:dateTime)
bibo:doi	10.1016/j.biotechadv.2017.05.002
bibo:pmid	28522213
has license	els-covid
sha1sum (hex)	235e5cda4dc7631fda5c27fd58f99ee0d261a0a0
schema:url	https://doi.org/10.1016/j.biotechadv.2017.05.002
resource representing a document's title	Harnessing self-assembled peptide nanoparticles in epitope vaccine design
has PubMed Central identifier	PMC7127164
has PubMed identifier	28522213
schema:publication	Biotechnology Advances
resource representing a document's body	covid:235e5cda4dc7631fda5c27fd58f99ee0d261a0a0#body_text
is schema:about of	named entity 'structures' named entity 'vaccine' named entity 'employed' named entity 'peptide' named entity 'terms' named entity 'nanoparticles' named entity 'immune response' named entity 'selection' named entity 'peptide' named entity 'nanoparticles' named entity 'PEPTIDE' covid:arg/235e5cda4dc7631fda5c27fd58f99ee0d261a0a0 named entity 'ADJUVANTICITY' named entity 'FUTURE' named entity 'YEARS' named entity 'SIZE' named entity 'STUDIES' named entity 'THEIR' named entity 'NATURAL' named entity 'PEPTIDES' named entity 'ART' named entity 'SPECIAL' named entity 'IMMUNOGENS' named entity 'PROPERTIES' named entity 'INTEREST' named entity 'STRUCTURES' named entity 'DIFFERENT' named entity 'RECENTLY' named entity 'TRADITIONAL' named entity 'EPITOPE' named entity 'TAILORED' named entity 'DUE TO' named entity 'TO PROVIDE' named entity 'SPECIFICITY' named entity 'DESIGN' named entity 'AREA' named entity 'NANOPARTICLES' named entity 'IMMUNE RESPONSE' named entity 'VACCINATION' named entity 'ONE OF' named entity 'SELF' named entity 'UNIQUE' named entity 'PEPTIDE' named entity 'SHEET' named entity 'USE' named entity 'SECONDARY' named entity 'ADVANTAGE' named entity 'LIMITED' named entity 'HELICAL' named entity 'APPROACHES' named entity 'WHICH VIRUS' named entity 'NANOTECHNOLOGY' named entity 'WIDE' named entity 'ALLOWS' named entity 'SURFACE' named entity 'TOXIC' named entity 'PROGRESS' named entity 'ALTERNATIVE' named entity 'EMPLOYED' named entity 'FLEXIBILITY' named entity 'SUFFER' named entity 'NANOPARTICLES' named entity 'ENGINEERING' named entity 'VACCINE DESIGN' named entity 'MEDICAL HISTORY' named entity 'OVERVIEW' named entity 'BIODEGRADABILITY' named entity 'RELATED' named entity 'VACCINE DESIGN' named entity 'SELF' named entity 'EPITOPE' named entity 'SUCCESSFUL' named entity 'DISPLAY' named entity 'DE NOVO' named entity 'VARIETY' named entity 'ADJUVANTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software